ArticleBrain, behavior, & immunity - health2025
Prednisolone add-on in early phase schizophrenia: A randomized, double-blind, placebo-controlled pilot study.
Article in Brain, behavior, & immunity - health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: New pharmacological treatment strategies are urgently needed for schizophrenia since current antipsychotic medications have limitations related to efficacy, tolerability, and disease course modification. Different lines of evidence converge on aberrant activity of the immune system, but translation into new treatment is still pending. Studies investigating the antipsychotic properties of less potent anti-inflammatory drugs have provided equivocal findings. A potent agent like prednisolone might be better suited for establishing proof-of-concept that dampening of inflammation may be beneficial in schizophrenia. Methods: In this double-blind multicentre pilot study, 12 patients (aged 18-39) with schizophrenia maintained on stable antipsychotic regimens were randomized to prednisolone or placebo. Study medication was initiated with 40 mg/day and gradually tapered to zero over a period of 6 weeks. The primary outcome was difference in the Positive and Negative Syndrome Scale (PANSS) total score 6 weeks after baseline. Outcomes: In patients randomized to prednisolone (N = 6), a clear trend towards more pronounced reduction of psychotic symptoms was observed compared to the placebo group (N = 6). Difference in symptom severity per the PANSS total score after 6 weeks of add-on treatment was 15·4 (SD = 8·5, p = 0·101). For the PANSS general score, we observed a statistically significant difference of 12·5 (SD = 4·6, p = 0·021) at week 6. Safety and tolerability were acceptable for the duration of prednisolone treatment. Interpretation: These findings suggest beneficial effect of add-on prednisolone. However, this needs further replication in a larger sample for confirmation and to identify the mechanisms of action.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.